Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | AXL positive |
| Therapy | Bemcentinib |
| Indication/Tumor Type | acute myeloid leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL positive | acute myeloid leukemia | sensitive | Bemcentinib | Phase I | Actionable | In a Phase I trial, Bemcentinib (BGB-324) treatment inhibited Axl phosphorylation, resulted in complete response in 12.5% (1/8), partial response in 12.5% (1/8), and stable disease in 37.5% (3/8) of acute myeloid leukemia patients (J Clin Oncol 34, 2016 (suppl; abstr 2561)). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| A first-in-patient phase I study of BGB324, a selective Axl kinase inhibitor in patients with refractory/relapsed AML and high-risk MDS. | Full reference... |